Search PubMed⌕ Search

Biomedical subjects

F Cox

Publications and source records attributed to F Cox.

84 records · Page 5Linked to original sources
PubMedDate not supplied

Nocardia asteroides brain abscess following mastoidectomy.

Nocardia asteroides brain abscess occurred after mastoidectomy and tympanoplasty in a previously healthy 10-year-old boy. Combined surgical excision and trimethoprim/sulfamethoxazole therapy resulted in significant improvement.

Brain Abscess↗
PubMedDate not supplied

Vowel change in Australian English.

The dynamic nature of vowel systems has recently been investigated in several English dialects confirming that phonetic disruptions often have systemic consequences and suggesting that change follows predictable patterns of movement. The present paper examines the nature of vowel change in Australian English by comparing two sets of data from different subjects at each end of a 25-year interval. A series of multivariate analyses of variance reveals significant acoustic differences between the two sets of data providing strong evidence for systemic effects. The analysis also indicates the presence of chain and parallel shifts within vowel classes as well as a close correspondence between monophthong and diphthong movement in phonetic space. The observed monophthong/diphthong relationships suggests that change in one class of vowels impacts on the other in a parallel fashion in this dialect of English.

Adolescent↗
PubMedDate not supplied

Ondansetron: a cost-effective advance in anti-emetic therapy.

A cost-effectiveness analysis is one form of full economic evaluation where drug acquisition costs and the costs that are incurred as a result of using a particular treatment are assessed together with clinical efficacy. This paper reviews two such studies. One of the studies was a prospective randomised cost-effectiveness study which compared ondansetron (8 mg i.v. 0, 4 and 8 h following chemotherapy) with metoclopramide (3 mg/kg i.v. followed by an infusion of 0.5 mg/kg/h for 8 h) over the first 24 h following chemotherapy in hospitalised patients receiving highly emetogenic chemotherapy. This study showed that the cost per successfully treated patient (defined in this study as having < or = 1 emetic episode and no adverse events) for these 2 treatments were approximately equal: ondansetron pounds 95 and metoclopramide pounds 92. The second study was an economic evaluation based on data collected over a 5-day period following cyclophosphamide-based chemotherapy given on an outpatient basis for the treatment of breast cancer. Patients received an intravenous dose of 16 mg dexamethasone with either 8 mg ondansetron or 60 mg metoclopramide intravenously before chemotherapy followed by oral dosing with 8 mg ondansetron or 20 mg metoclopramide 3 times daily for 5 days. The costs per successfully treated patient (defined in this study as no vomiting or retching episodes and no anti-emetic-related adverse events during the 5-day period) were comparable: ondansetron pounds 184 and metoclopramide pounds 160. A recent study has established that ondansetron (8 mg) given orally twice daily is as effective as the same dose given 3 times a day. A sensitivity analysis using the cost of an ondansetron twice daily regimen showed that ondansetron is more cost-effective than metoclopramide (pounds 133 vs. pounds 160). These cost effectiveness studies have shown that ondansetron is at least as cost-effective as metoclopramide and simplified ondansetron dosing schedules render ondansetron more cost-effective. These full economic evaluations illustrate that drug acquisition costs can be a misleading guide to the economic impact of antiemetics.

Breast Neoplasms↗